Introduction
============

Efavirenz provides the backbone to first-line highly active antiretroviral treatment (HAART) in South Africa. HAART effectively suppresses human immunodeficiency syndrome virus (HIV) replication in the majority of patients (Mocroft et al., [@B23]). Thus, many HIV-infected patients are now living longer compared to the pre-HAART period. However, long term antiretroviral (ARV) treatment has its own challenges such as drug--drug interactions and the development of adverse drug reactions (ADRs). Drug--drug interactions are a major problem in HIV/AIDS patients due to co-morbidities such as TB and malaria.

FDA-approved ARV drugs, including efavirenz, indinavir, nelfinavir, and ritonavir are affected by the activities of the multidrug transporter P-glycoprotein (P-gp), coded by the *ABCB1* gene. *ABCB1* forms part of the ATP-binding cassette gene family with about 50 members and is located on chromosome 7q21.12, spanning 209.6 kb, and containing 29 exons (Bodor et al., [@B4]). Genetic variation in the *ABCB1* gene is known to alter mRNA stability or splicing activity (Fung and Gottesman, [@B11]). The three most common single nucleotide polymorphisms (SNPs) in the protein coding region of *ABCB1* are *1236C*\>*T* (*rs1128503*), *3435C*\>*T* (*rs1045642*), and *2677G*\>*T/A* (*rs2032582*), where multiple alleles have been reported. The *1236C*\>*T* SNP occurring in exon 13, does not result in an amino acid change, but may affect *ABCB1* expression through codon usage (Gu et al., [@B13]). The allele frequency of *1236T* variant ranges from 10% among South Africans (Dandara et al., [@B9]) to 90% among Asians (Ambudkar et al., [@B1]). The *2677G*\>*T/A* SNP results in a change from serine to alanine or threonine at residue 893, but the effect of the changes on protein function is uncertain. The *3435T* allele has been associated with reduced expression of P-gp, although it is synonymous (Meissner et al., [@B22]). Large inter-ethnic variability has been reported for the *3435C*\>*T* SNP with the *ABCB1 3435C* variant being the most frequent at 83, 58, 57, and 11% among Africans (Kenyans and Ghanaians), Asians (Chinese), Caucasians, and Yoruba individuals, respectively (Ameyaw et al., [@B2]). The *ABCB1 3435T* variant has been linked with good immune recovery in HIV/AIDS individuals, while the presence of the *ABCB1 2677T* variant has been strongly associated with virological failure (Motsinger et al., [@B24]). A few studies have suggested associations between *ABCB1* gene polymorphisms and variability in plasma efavirenz concentrations (Fellay et al., [@B10]; Mukonzo et al., [@B25]), but all the studies lack adequate sample size. There are conflicting reports on the effects of these SNPs on efavirenz treatment response (Cascorbi et al., [@B7]; Fellay et al., [@B10]; Cascorbi, [@B6]). Replication studies are thus necessary to understand the contribution of *ABCB1* gene variants to plasma efavirenz levels. Dandara et al. ([@B9]) showed that genetic variants in *ABCB1* are frequent in the South African population, and this study is a continuation further evaluating the clinical significance of these SNPs. Therefore, the aim of this study was to investigate the role of genetic polymorphisms in *ABCB1* on plasma efavirenz levels in HIV/AIDS patients in the South African population.

Results
=======

The mean age of the HIV/AIDS patients was 41.3 years, and more than 75% (*n* = 227) were female. Of the patients, 7 and 10% smoked and consumed alcohol. The clinical characteristic of the patients included viral load and CD-4 cell count (Table [1](#T1){ref-type="table"}).

###### 

**Clinical characteristics of the South African HIV/AIDS patients**.

  -------------------------------------------------------------------------
  Clinical characteristics                HIV/AIDS patients (*n* = 301)
  --------------------------------------- ---------------------------------
  Median HIV-RNA at baseline,\            26917.71 ± 27133.50 (25--98400)
  copies/mL ± SD (range)                  

  Median HIV-RNA at 6 months\             1518.52 ± 9004.10 (0--75000)
  post-initiation of HAART,\              
  copies/mL ± SD (range)                  

  Average CD-4 cell count at baseline,\   136.09 ± 113.24 (2--605)
  cells/μL ± SD (range)                   

  Average CD-4 cell count at 6 months\    261.76 ± 137.68 (28--775)
  post-initiation of HAART,\              
  cells/μL ± SD (range)                   

  ARV regimens                            

   3TC_TDF_EFV                            9

   AZT_3TV_EFV                            11

   d4T_3TC_EFV                            222

   d4T_3TC_LPVr                           18

   d4T_3TC_NVP                            22

  Average plasma efavirenz\               4.64 (0.6--22)
  concentration, μg/mL (range)            
  -------------------------------------------------------------------------

Comparison of allele frequencies among world populations
--------------------------------------------------------

The genotypes for all the SNPs were observed in the HIV/AIDS patients, except the *ABCB1* *61G/G* (*rs9282564*) genotype. All *ABCB1* SNPs were in Hardy--Weinberg Equilibrium (HWE). The *ABCB1 61A/G* (*rs9282564*), *3435T/T* (*rs1045642*), *4036G/G* (*rs3842*), *1236T/T* (*rs1128503*), *2677T/A*, and *2677G/A* (*rs2032582*) genotypes were present at frequencies of 0.006, 0.024, 0.036, 0.015, 0.004, and 0.004, respectively, among the South Africans. No individuals with an *ABCB1 3435A* allele was observed in the South African cohort (Table [2](#T2){ref-type="table"}), and this is similar to what was reported by Dandara et al. ([@B9]). The allele frequencies of SNPs in the South Africans were compared to the allele frequencies reported previously in other populations (Table [2](#T2){ref-type="table"}), available from previous studies or the HapMap project (<http://hapmap.ncbi.nlm.nih.gov/>).

###### 

**Allele frequencies in the South Africans compared to other populations**.

  Population                    Reference                            *N*   61G       1236T     3435T     2677T     2677A     4036G
  ----------------------------- ------------------------------------ ----- --------- --------- --------- --------- --------- ---------
  Black South Africans^\#^      (Dandara et al., [@B9])/This study   979   0.003     0.090     0.120     0.040     0.004     0.202
  Sotho/Tswana South Africans   This study                           127   0.000     0.106     0.110     0.012     0.004     0.165
  Xhosa South Africans          This study                           107   0.014     0.178\*   0.210\*   0.098\*   0.005     0.224
  Zulu South Africans           This study                           139   0.000     0.119     0.140     0.022     0.000     0.209
  Malawi                        Brown et al. ([@B5])                 30    N/A       N/A       0.210     0.000     0.000     N/A
  Yoruba                        Hapmap                               226   0.000     0.124     0.111     0.000\*   0.000     0.142
  Luhya                         Ikediobi et al. ([@B17])             89    N/A       0.110     N/A       N/A       N/A       N/A
  Maasai                        Ikediobi et al. ([@B17])             143   N/A       0.140     0.840\*   N/A       N/A       N/A
  African-American              Hapmap                               46    0.000     0.136     0.071     0.077     0.000     0.000\*
  Caucasian                     Hapmap                               226   0.100\*   0.451\*   0.571\*   0.340\*   0.042\*   0.142
  Gujarati Indian               Hapmap                               176   0.017     0.597\*   0.597\*   0.653\*   0.000     0.163
  Mexican                       Hapmap                               96    0.052\*   0.460\*   0.460\*   0.430\*   0.000     0.230
  Toscan                        Hapmap                               176   0.062\*   0.426\*   0.466\*   0.438\*   0.000     0.138
  Chinese                       Ikediobi et al. ([@B17])             45    0.000     0.680\*   0.580\*   N/A       N/A       N/A
  Japanese                      Hapmap                               90    0.000     0.587\*   0.459\*   0.552\*   0.000     0.320\*

*N/A, not available, \*statistically significant difference from the frequencies among the Black South African group^\#^*.

Correlation of genetic variation with plasma efavirenz concentration
--------------------------------------------------------------------

The *ABCB1 4036A/G* and *4036G/G* genotypes were associated with significantly decreased efavirenz levels (*P* = 0.0236), compared to the *4036A/A* genotype (Figure [1](#F1){ref-type="fig"}A). Fewer individuals with the *ABCB1 4036G/G* genotype changed treatment compared to the individuals with the *4036A/A* genotype (Table [3](#T3){ref-type="table"}). The *ABCB1 1236C/T* and *1236T/T* genotypes were associated with significantly higher plasma efavirenz concentrations, compared to the *1236C/C* genotype (*P* = 0.0282; Figure [1](#F1){ref-type="fig"}C). Compared to the *ABCB1 1236C/C* genotype, more individuals with the *1236T/T* genotype changed antiretroviral regimens 1 year post treatment initiation (Table [3](#T3){ref-type="table"}). No difference was observed when comparing individuals with efavirenz concentration above 4 μg/mL to those with concentrations below 4 μg/mL, with respect to change in treatment regimens (*P* = 0.571). No significant differences were observed in efavirenz concentrations between the *ABCB1 2677G*\>*T/A* and *ABCB1 3435C*\>*T* genotypes (Figures [1](#F1){ref-type="fig"}B,D).

![**(A--D)** *ABCB1 4036A/G* and G/G genotypes (*P* = 0.0236) are associated with reduced efavirenz levels, while *1236C/T* and T/T genotypes (*P* = 0.0282) are associated with increased efavirenz levels in South African HIV/AIDS patients. Only significant *P*-values (without Bonferroni correction), using the dominant genetic model, are shown.](fgene-03-00236-g001){#F1}

###### 

**Frequency of HIV/AIDS patients changing ART regimens within 3 months, 6 months and 1 year post-initiation of treatment[\*](#tfn1){ref-type="table-fn"}**.

  Genotype                         Treatment initiation (*n*)   3 months   *P*-value   6 months   *P*-value   1 year   *P*-value
  -------------------------------- ---------------------------- ---------- ----------- ---------- ----------- -------- -----------
  **EFV-CONTAINING ARV REGIMEN**                                                                                       
  3TC_TDF_EFV                      9                            0.11                   0.00                   0.11     
  AZT_3TC_EFV                      11                           0.00       0.182       0.09       0.993       0.18     0.898
  d4T_3TC_EFV                      222                          0.03                   0.05                   0.14     
  1236C/C                          192                          0.04                   0.05                   0.12     
  1236C/T                          44                           0.02       0.399       0.04       0.636       0.18     0.089
  1236T/T                          3                            0.00                   0.00                   0.50     
  3435C/C                          192                          0.04                   0.05                   0.13     
  3435C/T                          44                           0.00       0.387       0.05       0.962       0.16     0.653
  3435T/T                          3                            0.33                   0.00                   0.00     
  2677G/G                          229                          0.03                   0.06                   0.13     
  2677G/T                          7                            0.00       0.563       0.11       0.666       0.00     0.706
  2677T/A and G/A                  2                            0.00                   0.00                   0.50     
  4036A/A                          153                          0.03                   0.05                   0.14     
  4036A/G                          78                           0.03       0.987       0.06       0.834       0.14     0.852
  4036G/G                          8                            0.00                   0.00                   0.11     

*\*Only 282 patients had information on treatment regimens. *ABCB1 61A*\>*G* was excluded based on being monomorphic*.

Haplotype analysis
------------------

Haplotype and efavirenz plasma levels for each patient are presented in supplementary Table [A1](#TA1){ref-type="table"}. The haplotypes with respect to *1236C*\>*T*, *2677G*\>*T/A*, *3435C*\>*T*, and *4036A*\>*G* SNPs *C-G-C-A*, *C-G-C-G*, *C-G-T-G*, *T-G-C-A*, *T-G-T-A*, *T-G-T-G*, *T-T-T-A*, and *T-T-T-G* had the following frequencies in the HIV/AIDS patients; 0.67, 0.17, 0.04, 0.03, 0.06, 0.01, 0.001, and 0.01, respectively. The *ABCB1 T-G-T-A* haplotype had the highest mean plasma log~10~ efavirenz concentrations (0.90 μg/mL) compared to 0.49 and 0.65 μg/mL among patients with the *T-G-C-A* or *T-G-T-G* haplotypes, respectively (Figure [2](#F2){ref-type="fig"}). The efavirenz concentrations differed significantly between individuals with the *ABCB1 C-G-C-G* and *T-G-T-A* haplotypes (*P* = 0.007) and were still significant after Bonferroni's correction for multiple testing (cut-off significant *P* \< 0.01).

![**The effect of *ABCB1* haplotypes on plasma efavirenz concentrations**. Only significant *P*-values after Bonferroni's correction for multiple testing at significance *P* \< 0.01 are shown. The *ABCB1 C-A-C-A*, *C-T-C-A*, and *T-T-T-G* haplotypes were only observed once and thus excluded from the analysis.](fgene-03-00236-g002){#F2}

Univariate and multivariate regression analysis of efavirenz concentration
--------------------------------------------------------------------------

Univariate regression analysis was performed to determine the effect of age, gender, tobacco smoking, alcohol use, BMI at baseline, CD-4 cell count, log~10~ HIV-RNA levels, *ABCB1* haplotypes, *ABCB1 1236C*\>*T, 4036A*\>*G*, *3435C*\>*T*, and *2677G*\>*T/A* genotypes on plasma efavirenz concentrations (Table [4](#T4){ref-type="table"}). The genotypes of the four SNPs *1236C*\>*T*, *2677G*\>*T/A*, *3435C*\>*T*, and *4036A*\>*G* significantly predicted efavirenz concentration individually and were, thus, included in the multivariate analysis together with age, gender, tobacco smoking, alcohol use and BMI at baseline. Stepwise backward regression analysis was then performed to identify the minimum set of independent variables that are predictive of plasma efavirenz levels and to determine the relative contribution of each variable to efavirenz concentration variability. Only three independent variables remained in the final model with *P* \< 0.05, including *ABCB1 1236C*\>*T* (standardized regression coefficient = 0.24; *P* = 0.004), *ABCB1 4036A*\>*G* (standardized regression coefficient = 0.17; *P* = 0.009), and *ABCB1 2677G*\>*T/A* (standardized regression coefficient = 0.36; *P* = 0.047). The adjusted coefficient of determination (*R*^2^) for the regression was 0.16, indicating that 16% of the total variance in efavirenz concentrations was explained by the model. *ABCB1 1236C*\>*T, 4036A*\>*G*, and *2677G*\>*T/A* genotypes accounted for 29, 23, and 17% (respectively) of the total variance in plasma efavirenz concentrations. When repeating the multivariate analysis among female patients only, the adjusted coefficient of determination (*R*^2^) for the regression was 0.18, indicating that 18% of the total variance in efavirenz concentrations was explained by the model compared to the 16% explained when males and females were combined. However, the majority of HIV/AIDS patients in our study were female. Further statistical analysis comparing only the genetic- and non-genetic factors in the multivariate analysis, showed that the genetic factors alone explained 11% of variance in efavirenz levels, while the non-genetic factors only explained 3% compared to the 16% explained by the combined multivariate analysis.

###### 

**Univariate and multivariate regression analysis of efavirenz concentration**.

  -----------------------------------------------------------------------------------------------------
  Independent\                                         Log~10~ efavirenz,\      *P*     Contribution\
  variable                                             % (95%CI)                        in model (%)
  ---------------------------------------------------- ------------------------ ------- ---------------
  **UNIVARIATE**                                                                        

  Age                                                  0.01 (−0.06 to 0.08)     0.738   1.36

  Gender                                               −7.34 (−21.5 to 6.81)    0.307   0.12

  Tobacco smoking                                      −0.75 (−27.2 to 25.7)    0.956   2.60

  Alcohol use                                          −12.4 (−34.3 to 9.45)    0.263   11.9

  BMI at baseline                                      −0.70 (−2.16 to 0.76)    0.344   15.2

  CD-4 cell count at\                                  0.01 (−0.06 to 0.07)     0.793   --
  baseline                                                                              

  CD-4 cell count at\                                  −0.04 (−0.09 to 0.02)    0.186   --
  6 months                                                                              

  Log~10~ HIV-RNA at\                                  −11.9 (−21.3 to −2.44)   0.015   --
  baseline                                                                              

  Log~10~ HIV-RNA at\                                  10.4 (−7.26 to 28.0)     0.245   --
  6 months                                                                              

  Genotype\                                                                             
  (dominant model)                                                                      

  WT/WT                                                Ref                              

  ABCB1 1236C\>T                                       18.6 (2.02 to 35.2)      0.028   28.9

  ABCB1 4036A\>G                                       −14.8 (−27.5 to −2.01)   0.024   23.2

  ABCB1 3435C\>T                                       12.3 (−3.90 to 28.4)     0.136   0.12

  ABCB1 2677G\>T/A                                     −30.0 (−66.4 to 6.47)    0.106   16.6

  ABCB1 haplotypes                                     0.19 (−1.98 to 2.37)     0.862   --

  **MULTIVARIATE[^\#^](#tfn2){ref-type="table-fn"}**                                    

  ABCB1 1236C\>T                                       24.2 (7.81 to 40.6)      0.004   --

  ABCB1 4036A\>G                                       −16.6 (−29.1 to −4.15)   0.009   --

  ABCB1 2677G\>T/A                                     −35.9 (−71.3 to −0.43)   0.047   --
  -----------------------------------------------------------------------------------------------------

*^\#^Only significant covariates in the multivariate regression analysis are shown*.

Correlation of genetic variation with clinical parameters
---------------------------------------------------------

The average CD-4 cell count and viral load of individuals with the different genotypes for *ABCB1 1236C*\>*T* and *4036A*\>*G* were compared at baseline and also 6 months post-initiation of ARV therapy. The *ABCB1 1236C/T* and *4036G/G* genotypes were associated with the biggest decreases in viral load at 6 months (as shown in Figures [3](#F3){ref-type="fig"}A,B). None of the individuals with the *ABCB1 1236T/T* genotype had information on viral load at baseline or 6 months post-initiation of treatment. The *ABCB1 1236T* allele is associated with decreased expression of P-gp (Gow et al., [@B12]) and the *ABCB1 4036G* allele is associated with increased expression of P-gp. However, there were no major genotype associated differences in the recovery of the CD-4 cells with all genotypes showing a positive response (Figures [3](#F3){ref-type="fig"}C,D).

![**(A--D)** The effect of *ABCB1 4036A*\>*G* and *1236C*\>*T* on average HIV-RNA and CD-4 cell count at baseline and 6 months post-initiation of treatment.](fgene-03-00236-g003){#F3}

Discussion
==========

Heterogeneity of african populations in terms of genetics
---------------------------------------------------------

To our knowledge, the present study is the first to report on the allele and genotype frequencies of the *ABCB1 61A*\>*G, 2677G*\>*T/A*, and *4036A*\>*G* polymorphisms in the South African population. However, the other SNPs have been previously reported by Dandara et al. ([@B9]). This data contributes to the accumulation of information on genetic variants of pharmacogenetics relevance among Africans. The allele frequencies of the genetic polymorphisms in South Africans were also compared to the frequencies among other African, African-American, Asian, and Caucasian populations (Table [2](#T2){ref-type="table"}). As expected there are significant differences in the allele frequencies between African populations and Caucasians, for example, the allele frequency of the *ABCB1 3435T* allele in African populations ranges from 0.07 to 0.12, but is present at a frequency of almost 0.6 in Caucasian individuals. Differences in allele frequencies between the South African population compared with other African populations were also observed. The allele frequencies of the *ABCB1 4036G*, *2677T*, and *2677A* alleles were different to the frequencies reported in the Yoruba individuals (*P* \< 0.0001). The differences in allele frequencies between the African and Caucasian individuals show that therapeutic drugs, including efavirenz, may not have similar effectiveness in different populations when given at standard dosages. Similarly, fine scale genetic structure exists within the African population which, therefore, should not be treated as one population.

Implications for disease or drug treatment and possible development of diagnostic tools
---------------------------------------------------------------------------------------

We observed lower plasma efavirenz concentrations among individuals with the *ABCB1 4036A/G* and *4036G/G* genotypes and this could perhaps be as a result of the disruption of a miRNA binding site in the 3′UTR of *ABCB1*. Five poorly conserved miRNAs namely; miR-129, miR-491, miR-4795, miR-561, and miR-4717 have been predicted to target the 3′UTR region surrounding the *ABCB1 4036A*\>*G* SNP using the TargetScanHuman 6.1 miRNA target prediction software. Disruption of these sites could potentially cause reduced transport of efavirenz by *ABCB1* resulting in lower plasma efavirenz levels. In a different study among Ugandans, the *ABCB1 4036A/G* and *4036G/G* genotypes were associated with higher efavirenz bioavailability (Mukonzo et al., [@B25]). In the current study, *ABCB1 1236C/T* and *1236T/T* genotypes were associated with high plasma efavirenz concentrations, but there are conflicting reports on the effect of *ABCB1 1236C*\>*T* genotypes in tacrolimus, cyclosporine, and sirolimus drug responses (Kuzuya et al., [@B18]; Anglicheau et al., [@B3]; Haufroid et al., [@B16]), making it difficult to draw conclusions. There are conflicting reports as well for the role or effects of *ABCB1 2677G*\>*T/A* and *3435C*\>*T* polymorphisms (Schwab et al., [@B27]; Leschziner et al., [@B19]). Haas et al. ([@B15]) reported an association between the *ABCB1 3435T/T* genotype and a decreased likelihood of virologic failure and decreased resistance to efavirenz, but not with plasma efavirenz exposure.

Clinical parameters such as CD-4 cell count, viral load, disease stage, hemoglobin, AST, and ALT levels were used as indicators of ARV treatment efficacy, underlying liver disease and disease progression in the HIV/AIDS patients. As expected, efavirenz-containing HAART led to a general (48%) increase in CD-4 cell count (cells/μL) and a 94% decrease in viral load (copies/mL) when baseline levels where compared to levels at 6 months post-initiation of treatment. Failure of reduction in viral load and emergence of opportunistic infections after 6 months led to ARV switching. Sustained viral load after 6 months and the presence of opportunistic infections are indications of possible treatment failure or non-adherence. On the other hand, other studies have shown that high plasma efavirenz concentrations are associated with development of adverse drug events leading to drug discontinuation (Marzolini et al., [@B21]; Lubomirov et al., [@B20]; Wyen et al., [@B31]).

Conclusion
==========

The current study showed that the drug transporter *ABCB1* contributes in predicting response to efavirenz treatment in the South African HIV/AIDS population. The *ABCB1 4036A*\>*G* and *1236C*\>*T* polymorphisms were significantly correlated with low and high plasma efavirenz concentration levels, respectively. However, this data should be taken together with the variation in *CYP2B6* which has a profound effect on efavirenz metabolism. The *CYP2B6 516G*\>*T* SNP is known to be associated with high plasma efavirenz levels and the combined effect of *CYP2B6* together with *ABCB1* SNPs will be more informative in predicting response to efavirenz treatment. This strongly supports the development of a pharmacogenetic suite of gene variants to assist in deciding the HAART regimen for HIV/AIDS treatment in a clinical setting as well as the starting ARV dosage.

Materials and Methods
=====================

Research participants
---------------------

All participants provided written informed consent and study approval was obtained from the University of Cape Town Health Science Faculty Research Ethics Committee, Cape Town, South Africa and the University of Witwatersrand Human Research Ethics Committee, Gauteng, South Africa. The research was performed in accordance with the guidelines of the Helsinki Declaration of 2008. Two hundred and eighty-two (*n* = 282) South African HIV/AIDS patients receiving efavirenz-based treatment for at least 6 months, were recruited to participate in this study. All subjects were of Bantu origin and comprised of Sotho/Tswana from Gauteng and Xhosa subjects from the Western Cape Province, South Africa. All subjects gave information on their ethnicity, age, health status (including self-reported adherence to treatment or pill counts), dietary, and smoking habits.

A 5 mL whole blood sample was obtained from each subject, and used for plasma sample collection as well as DNA extraction. DNA was isolated using a salting-out method adapted from Gustafson et al. ([@B14]) or the GenElute™ Blood Genomic DNA Kit (Sigma-Aldrich, St. Louis, MO, USA). Steady-state plasma samples were available for 137 HIV/AIDS patients 12--16 h post dose with efavirenz. Plasma efavirenz concentrations were determined by LC/MS/MS (API 4000 triple quadrupole MS/MS Applied Biosystems, South Africa) according to the method by Chi et al. ([@B8]).

Selection of SNPs and genotyping methods used
---------------------------------------------

Five previously reported SNPs in *ABCB1* \[GenBank accession: NM_000927.4\], namely *61A*\>*G, 1236C*\>*T, 2677G*\>*T/A*, *3435C*\>*T*, and *4036A*\>*G* were selected for investigation based on having minor allele frequencies above 10% in the African-Americans, South African, or other African populations and were genotyped using SNaPshot mini-sequencing (Table [5](#T5){ref-type="table"}).

###### 

**PCR and SNaPshot amplification conditions for *ABCB1* SNPs (GenBank accession: NM_000927.4)**.

  SNP          Primer sequence (5′-3′)                                     Ta (°C)   PCR product   References
  ------------ ----------------------------------------------------------- --------- ------------- ------------------------
  4036A\>G     F: CCTCAGTCAAGTTCAGAGTCTTCA                                 54°C      297           Designed
               R: TCACAGGCAGTTGGACAAG                                                              
               SNaPshot primer: TCTTGGCAGAAACTGCAAAAGGAGATTGAT                                     
  3435C\>T     F: ACTCTTGTTTTCAGCTGCTTG                                    54°C      230           Rhodes et al. ([@B26])
               R: AGAGACTTACATTAGGCAGTGACTC                                                        
               SNaPshot primer: ACTCGTCCTGGTAGATCTTGAAGGG                                          
  2677G\>T/A   F: ATGGTTGGCAACTAACACTGTTA                                  54°C      206           Rhodes et al. ([@B26])
               R: AGCAGTAGGGAGTAACAAAATAACA                                                        
               SNaPshot primer: CTTCGACCTAAGTGGAGAATGAGTTATTCTAAGGA                                
  1236C\>T     F: TGTGTCTGTGAATTGCCTTGAAG                                  51°C      228           Rhodes et al. ([@B26])
               R: CCTCTGCATCAGCTGGACTGT                                                            
               SNaPshot primer: TTAATTAATCAATCATATTTAGTTTGACTCACCTTCCCAG                           
  61A\>G       F: CTGCGGTTTCTCTTCAGGTC                                     51°C      149           Designed
               R: GATTCCAAAGGCTAGCTTGC                                                             
               SNaPshot primer: CTCCTTTGCTGCCCTCAC                                                 

Each PCR reaction contained, 50 ng of genomic DNA, 1X Green GoTaq Flexi Reaction Buffer (Promega Corporation, Madison, WI, USA), 0.2 mM of each of the deoxynucleotide triphosphates (dNTPs; Bioline, London, UK); 1.5 mM MgCl~2~ (Promega Corporation, Madison, WI, USA); 40 pmol of the forward and reverse primers (Integrated DNA Technologies, Inc., Coralville, IA, USA); 1 U of GoTaq Flexi DNA Polymerase (Promega Corporation, Madison, WI, USA). The PCR reactions were carried out using a "MyCycler Thermal cycler" from Bio-Rad. PCR conditions were as follows: 3 min at 94°C; 40 cycles of 94°C for 30 s, the annealing temperature specific to each SNP for 30 s, 72°C for 50 s; and 10 min at 72°C for final extension.

Five microliters of each PCR product was pooled and 10 μL of the combined PCR products were cleaned using 1.5 U shrimp alkaline phosphatase (Fermentas Life Sciences, Burlington, Canada) and 2 U *ExoI* (Fermentas Life Sciences, Burlington, Canada) in a total reaction volume of 20 μL. The shrimp alkaline phosphatase and *ExoI* reaction was incubated at 37°C for 1 h and the enzymes were inactivated at 75°C for 15 min. SNaPshot single base extension of the genetic polymorphisms was performed on the "GeneAmp^®^ PCR System 9700 version 3.08′′ (Applied Biosystems, Carlsbad, CA, USA) using the SNaPshot cycling programme as 96°C for 10 s, and then repeated for 25 cycles at 50°C for 5 s and 60°C for 30 s. The SNaPshot reaction (10 μL) contained 1 μL ABI Prism^®^ SNaPshot™ Multiplex Kit (Applied Biosystems, CA, USA) and the pooled internal SNaPshot primers (Integrated DNA Technologies, Inc., Coralville, IA, USA). Following the SNaPshot reaction, the clean-up reaction was repeated using 1 U shrimp alkaline phosphatase using cycling conditions as mentioned before, and capillary electrophoresis was performed using a ABI 3130xl Genetic Analyzer (Applied Biosystems, Carlsbad, CA, USA). SNaPshot results were analyzed on the GeneMapper © Software version 4.1 (Applied Biosystems, Carlsbad, CA, USA).

Statistical analysis
--------------------

Statistical analysis was performed using the Graphpad Prism (Version 5, GraphPad Software Inc., San Diego, CA) and STATA (Version 11, StatSoft, USA) statistical programs. *ABCB1* haplotypes were inferred using Phase v2.1 (Stephens et al., [@B30]; Stephens and Donnelly, [@B28]; Stephens and Scheet, [@B29]). Pearson's χ^2^-test and Fisher's exact test were used to compare the allele frequencies to results previously published in populations of different ethnicity. Fisher's exact test was also used to compare change in treatment regimen between the *ABCB1* genotypes. One-way analysis of variance, followed by Bonferroni's multiple comparison tests, was used to determine the effect of *ABCB1* haplotypes on plasma log~10~ efavirenz levels. Genotypes were dichotomized according to the dominant genetic model (wildtype = 0 and heterozygote/homozygote variants = 1). Univariate regression analysis was applied to log~10~ efavirenz concentrations as dependant variable and the percentage change in efavirenz levels, with the 95% CI, was calculated as 100 × regression coefficient. Multivariate regression analysis was performed by including covariates from the univariate analysis, followed by stepwise backward removal. TargetScanHuman 6.1 miRNA target prediction software were used to predict miRNA binding to the *ABCB1 3′UTR*. The following equation was used to calculate the sample size required to achieve a 99% confidence-interval: *N* = \[DEFF \* Np(1−*p*)\]/\[(d2/Z21−α/2 \* (*N*−1) + *p* \* (1−*p*)\]. DEFF is defined as the design effect, *Z* is the value for 99% confidence, *d* is an α-value = 0.05, while *p* is the frequency of the variant allele. A DEFF-value of 1 was used for random sampling, a *Z*-value of 1.96 and allele frequency of 0.1 was used to calculate the sample size of *N* = 239 samples. All statistical tests were performed two tailed, and statistical significance was defined as *P* \< 0.05.
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###### 

***ABCB1* haplotype composition for each HIV/AIDS patient where steady-state plasma efavirenz levels were available**.

  ------------------------------------------------------------------------------
  HIV/AIDS\   ABCB1 haplotype\                              Log~10~ efavirenz\
  patients    combination[\*](#tfn3){ref-type="table-fn"}   levels (μg/mL)
  ----------- --------------------------------------------- --------------------
  1           C-G-C-A/C-G-C-A                               0.111

  2           C-G-C-A/C-G-C-A                               0.838

  3           C-G-C-A/C-G-T-A                               0.023

  4           C-G-C-A/C-G-C-A                               −0.013

  5           C-G-C-A/C-G-C-A                               0.676

  6           C-G-C-A/C-G-C-G                               0.507

  7           C-G-C-A/C-G-T-A                               0.275

  8           C-G-C-A/C-G-C-G                               0.199

  9           C-G-C-A/C-G-C-G                               0.428

  10          C-G-C-A/C-G-C-G                               0.327

  11          C-G-C-A/C-G-T-A                               −0.229

  12          C-G-C-A/C-G-C-G                               0.917

  13          C-G-C-A/C-G-C-G                               0.208

  14          C-G-C-A/C-G-C-G                               0.415

  15          C-G-C-A/C-G-C-G                               0.478

  16          C-G-C-A/C-G-C-A                               0.321

  17          C-G-C-A/C-G-C-G                               0.276

  18          C-G-C-A/T-G-T-A                               0.624

  19          C-G-C-A/C-G-T-A                               1.083

  20          C-G-C-A/C-G-C-G                               0.170

  21          C-G-C-A/C-G-C-G                               0.445

  22          C-G-C-A/C-G-T-A                               0.611

  23          C-G-C-A/C-G-C-G                               0.419

  24          C-G-C-A/C-G-C-G                               0.558

  25          C-G-C-A/C-G-C-A                               0.622

  26          C-G-C-A/C-G-C-A                               0.267

  27          C-G-C-G/C-G-C-G                               0.107

  28          C-G-C-A/T-G-T-G                               1.170

  29          C-G-C-A/C-G-C-A                               0.083

  30          C-G-C-A/C-G-C-A                               0.390

  31          C-G-C-A/C-G-C-A                               0.408

  32          C-G-C-A/C-G-C-A                               0.720

  33          C-G-C-A/C-G-C-A                               0.378

  34          C-G-C-A/C-G-T-A                               0.157

  35          C-G-C-A/C-G-C-G                               0.172

  36          C-G-C-A/C-G-C-A                               0.029

  37          C-G-C-A/C-G-C-A                               0.902

  38          C-G-C-A/C-G-C-A                               0.380

  39          C-G-C-A/C-G-C-A                               1.016

  40          C-G-C-A/C-G-C-A                               0.880

  41          C-G-C-A/T-G-C-A                               0.407

  42          C-G-C-A/C-G-C-G                               0.819

  43          C-G-C-A/C-G-C-A                               0.780

  44          C-G-C-A/C-G-C-A                               1.316

  45          C-G-C-A/C-G-C-G                               0.112

  46          C-G-C-G/T-G-C-A                               0.554

  47          C-G-C-A/C-G-C-G                               0.419

  48          C-G-C-A/C-G-C-A                               0.352

  49          C-G-C-A/C-G-C-A                               1.141

  50          C-G-C-A/T-T-T-G                               0.539

  51          C-G-C-A/T-G-T-A                               1.303

  52          C-G-C-A/C-G-C-A                               0.927

  53          C-G-C-A/C-G-C-G                               0.298

  54          C-G-C-A/C-G-C-G                               0.892

  55          C-G-C-A/C-G-C-A                               0.422

  56          C-G-C-A/T-G-T-G                               0.899

  57          C-G-C-A/T-G-C-A                               0.428

  58          C-G-C-G/C-G-C-G                               0.723

  59          C-G-C-A/T-T-T-G                               0.205

  60          C-G-C-A/C-G-C-A                               0.353

  61          C-G-C-A/C-G-C-G                               0.252

  62          C-G-C-G/C-G-C-G                               0.499

  63          C-G-C-A/C-G-C-A                               0.442

  64          C-G-C-A/T-G-T-G                               0.095

  65          C-G-C-A/C-G-C-A                               0.649

  66          C-G-C-G/T-G-C-A                               0.405

  67          C-G-C-A/C-G-C-A                               0.495

  68          C-G-C-A/C-G-C-G                               0.413

  69          C-G-C-A/C-G-C-A                               0.619

  70          C-G-C-A/C-G-C-A                               0.196

  71          C-G-C-A/T-G-T-A                               1.306

  72          C-G-C-A/C-G-C-G                               0.328

  73          C-G-C-A/C-G-C-A                               0.932

  74          C-G-C-A/C-G-C-A                               0.315

  75          C-G-C-A/C-G-C-A                               1.322

  76          C-G-C-A/C-G-C-A                               0.585

  77          C-G-C-A/C-G-C-A                               0.623

  78          C-G-C-G/C-G-T-A                               0.215

  79          C-G-C-A/C-G-C-A                               1.125

  80          C-G-C-A/C-G-C-A                               0.294

  81          C-G-C-A/T-G-T-G                               0.947

  82          C-G-C-A/T-G-T-A                               1.160

  83          C-G-C-A/C-G-C-A                               0.989

  84          C-G-C-A/C-G-C-A                               0.072

  85          C-G-C-A/C-G-C-A                               0.415

  86          C-G-C-A/C-G-C-A                               0.214

  87          C-G-C-A/C-G-C-A                               0.874

  88          C-G-C-A/C-G-C-G                               0.450

  89          C-G-C-A/C-G-C-A                               −0.140

  90          C-G-C-A/C-G-T-A                               1.037

  91          C-G-C-A/C-G-C-A                               0.381

  92          C-G-C-A/C-G-C-A                               −0.143

  93          C-G-C-A/C-G-C-G                               0.076

  94          C-G-C-A/C-G-C-G                               0.924

  95          C-G-C-A/C-G-C-G                               0.033

  96          C-G-C-A/C-G-C-A                               0.946

  97          C-G-C-A/C-G-C-A                               −0.164

  98          C-G-C-G/T-G-C-A                               −0.029

  99          C-G-C-A/C-G-C-A                               −0.105

  100         C-G-C-A/C-G-C-A                               0.645

  101         C-G-C-A/C-G-C-A                               0.911

  102         C-G-C-A/C-G-C-G                               0.394

  103         C-G-C-A/T-G-T-G                               0.274

  104         C-G-C-A/C-G-C-G                               0.313

  105         C-G-C-A/C-G-C-G                               0.164

  106         C-G-C-A/C-G-T-A                               0.371

  107         C-G-C-A/C-G-C-A                               0.264

  108         C-G-C-A/C-T-C-A                               0.010

  109         C-G-C-A/C-G-C-G                               0.111

  110         C-G-C-A/C-G-C-A                               1.109

  111         C-G-C-A/C-G-C-A                               0.671

  112         C-G-C-A/C-G-C-A                               0.324

  113         C-G-C-A/C-G-C-A                               0.431

  114         C-G-C-A/T-G-C-A                               0.431

  115         C-G-C-A/C-G-C-A                               0.566

  116         C-G-C-A/C-G-C-A                               0.780

  117         C-G-C-A/T-G-T-G                               0.516

  118         C-G-C-A/C-G-C-G                               0.276

  119         T-G-C-A/T-G-T-A                               0.541

  120         C-G-C-A/C-G-C-A                               0.821

  121         C-G-C-A/T-G-T-A                               1.038

  122         C-G-C-A/C-G-C-A                               0.364

  123         C-G-C-A/C-G-C-A                               1.106

  124         C-G-C-A/C-G-C-A                               0.584

  125         C-G-C-A/C-G-C-A                               1.093

  126         C-G-C-A/C-G-C-A                               0.692

  127         C-G-C-A/C-G-C-G                               0.340

  128         C-G-C-A/C-G-C-A                               0.751

  129         C-G-C-A/C-G-C-A                               0.192

  130         C-A-C-A/C-G-C-A                               0.092

  131         C-G-C-A/C-G-C-A                               0.192

  132         C-G-C-A/C-G-C-A                               0.106

  133         C-G-C-A/C-G-C-A                               0.941

  134         C-G-C-A/C-G-C-A                               0.204

  135         C-G-C-A/T-G-C-A                               1.348

  136         T-G-C-A/T-G-T-A                               0.329

  137         C-G-C-A/C-G-C-G                               0.271
  ------------------------------------------------------------------------------

*\**ABCB1* haplotypes with respect to *1236C*\>*T-2677G*\>*T/A-3435C*\>*T-4036A*\>*G*, *61A*\>*G* was excluded from the haplotype based on being monomorphic*.
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